Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.36 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.36 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.36 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL28488274 | 1.00 | TSHR (0.56) | TSHRCYP3A4CPB2BLMLMNA | |
| Cadaverine Tartrate SCHEMBL25240399 | 0.97 | TSHR (0.53) | TSHRCYP3A4CPB2BLMLMNA | |
| Cadaverine Tartrate SCHEMBL786877 | 0.85 | TSHR (0.67) | TSHRBLMLMNAMAPTTDP1 | |
| Cadaverine Tartrate SCHEMBL342524 | 0.85 | TSHR (0.67) | TSHRBLMLMNAMAPTTDP1 | |
| Lactic Acid SCHEMBL14484983 | 0.81 | TP53 (0.58) | TSHRCYP3A4CPB2BLMLMNA | |
| Cadaverine Tartrate SCHEMBL1834853 | 0.80 | TSHR (0.59) | TSHRBLMLMNAMAPTTDP1 | |
| Cadaverine Tartrate SCHEMBL1833811 | 0.80 | TSHR (0.59) | TSHRBLMLMNAMAPTTDP1 | |
| Tartaric Acid SCHEMBL31538119 | 0.80 | TSHR (0.59) | TSHRBLMLMNAMAPTTDP1 | |
| Cadaverine Tartrate SCHEMBL49514 | 0.79 | CYP3A4 (0.40) | TSHRCYP3A4CPB2BLMLMNA | |
| Cysteamine SCHEMBL5502656 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 831 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576050-B2 | Dosage regime | NOVABIOTICS LIMITED (GB) | 2026-03-17 | — | — | US | claimed |
| US-20250388739-A1 | COMPOSITION, CURED SUBSTANCE, AND OPTICAL MEMBER | FUJIFILM CORPORATION (JP) | 2025-12-25 | — | — | US | claimed |
| EP-3525761-B1 | FORMULATIONS OF CYSTEAMINE AND CYSTEAMINE DERIVATIVES | RECORDATI IND CHIMICA E FARMACEUTICA SPA (IT) | 2025-06-25 | — | — | EP | claimed |
| WO-2025062426-A1 | CYSTEAMINE OPHTHALMIC FORMULATION WITH IMPROVED SHELF LIFE AND IN-USE PERIOD | TOYAJA LIFE SCIENCES (IN) | 2025-03-27 | — | — | WO | claimed |
| WO-2025059302-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT AND MODULATION OF ACUTE AND CHRONIC SYMPTOMS OF MITOCHONDRIAL DISEASE AND DYSFUNCTION | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-03-20 | — | — | WO | claimed |
| EP-3866775-B1 | CYSTEAMINE FOR USE IN THE TREATMENT OF LUNG DISEASES | NOVABIOTICS LTD (GB) | 2025-03-19 | — | — | EP | claimed |
| WO-2025028373-A1 | COMPOSITION, RESIN COMPOSITION, LIQUID COMPOSITION, DYE COMPOUND, AND OPTICAL MATERIAL | 富士フイルム株式会社 | 2025-02-06 | — | — | WO | claimed |
| US-20250000817-A1 | Methods of Treating Mitochondrial Dysfunction | RIBONOVA INC. (US) | 2025-01-02 | — | — | US | claimed |
| US-20240398761-A1 | Use of Chloroquine Compounds for Treatment of Inflammatory Conditions | EIGER GROUP INTERNATIONAL, INC. | 2024-12-05 | — | — | US | claimed |
| EP-4457210-A2 | PROCESS FOR THE PREPARATION OF CYSTEAMINE BITARTRATE AND PRODUCT SO OBTAINED | Recordati Industria Chimica E Farmaceutica SPA (IT) | 2024-11-06 | — | — | EP | claimed |
| US-9173851-B1 | Delayed release cysteamine bead formulation, and methods of making and using same | RAPTOR PHARMACEUTICALS INC. (US) | 2015-11-03 | — | — | US | claimed |
| US-20150290149-A1 | ENTERICALLY COATED CYSTEAMINE, CYSTAMINE AND DERIVATIVES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-10-15 | — | — | US | claimed |
| US-20150290139-A1 | Delayed Release Cysteamine Bead Formulation, and Methods of Making and Using Same | HORIZON THERAPEUTICS U.S. HOLDING LLC | 2015-10-15 | — | — | US | claimed |
| US-20150290150-A1 | ENTERICALLY COATED CYSTEAMINE, CYSTAMINE AND DERIVATIVES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-10-15 | — | — | US | claimed |
| US-20150056712-A1 | Methods for Analyzing Cysteamine Compositions | HORIZON THERAPEUTICS U.S. HOLDING LLC | 2015-02-26 | — | — | US | claimed |
| WO-2014204887-A1 | METHODS FOR ANALYZING CYSTEAMINE COMPOSITIONS | RAPTOR PHARMACEUTICALS INC. (US) | 2014-12-24 | — | — | WO | claimed |
| WO-2014204881-A1 | DELAYED RELEASE CYSTEAMINE BEAD FORMULATION | RAPTOR PHARMACEUTICALS, INC. (US) | 2014-12-24 | — | — | WO | claimed |
| US-20140370085-A1 | Delayed Release Cysteamine Bead Formulation, and Methods of Making and Using Same | HORIZON THERAPEUTICS U.S. HOLDING LLC | 2014-12-18 | — | — | US | claimed |
| US-20140275279-A1 | CYSTEAMINE IN THE TREATMENT OF FIBROTIC DISEASE | SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2014-09-18 | — | — | US | claimed |
| WO-2013062544-A1 | CYSTEAMINE IN THE TREATMENT OF FIBROTIC DISEASE | SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2013-05-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576050-B2 | Dosage regime | CFTR, SLC26A4, SLC7A11 | ADRB2 829/4885ADRB1 681/4885ADRA2A 1094/4885 |
| US-20250388739-A1 | COMPOSITION, CURED SUBSTANCE, AND OPTICAL MEMBER | RECQL, VKORC1L1, RBP1 | ADRB2 2052/4885ADRB1 1160/4885ADRA2A 1505/4885 |
| US-20250000817-A1 | Methods of Treating Mitochondrial Dysfunction | SLC25A20, NDUFAB1, HAGH | ADRB2 2016/4885ADRB1 2136/4885ADRA2A 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.